Search

Displaying results 5411 - 5420 of 10000 in total
  1. Drug

    AOC-1020

    go.drugbank.com/drugs/DB18621
    Investigational

    AOC-1020 is an antibody oligonucleotide conjugate, comprised of a human transferrin receptor 1 targeting, effector function null, humanized IgG1 antibody, a MCC maleimide linker, and a double-stranded

    Synonyms: An antibody oligonucleotide conjugate, comprised of a human transferrin receptor 1 targeting, effector function null, humanized IgG1 antibody, a MCC maleimide linker, and a double-stranded siRNA oligonucleotide
  2. Drug

    Afimkibart

    go.drugbank.com/drugs/DB18718
    Investigational

    RVT-3101 is a fully human monoclonal antibody targeting vascular endothelial growth inhibitor, also known as TNF-like ligand 1A (TL1A) and TNF superfamily member 15.

  3. Drug

    Tifcemalimab

    go.drugbank.com/drugs/DB18914
    Investigational

    Tifcemalimab is under investigation in clinical trial NCT06095583 (Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell

  4. Drug

    Tiamenidine

    go.drugbank.com/drugs/DB19607
    Experimental

    Tiamenidine is a small molecule drug. The usage of the INN stem '-nidine' in the name indicates that Tiamenidine is a a2 adrenoreceptor agonist. … Tiamenidine has a monoisotopic molecular weight of 215.03 Da.

  5. Drug

    SAR-125844

    go.drugbank.com/drugs/DB15382
    Investigational

    SAR-125844 is under investigation in clinical trial NCT01391533 (Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors).

  6. Drug

    Birtamimab

    go.drugbank.com/drugs/DB16414
    Investigational

    Birtamimab is under investigation in clinical trial NCT02312206 (The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis).

  7. Drug

    GB-13

    go.drugbank.com/drugs/DB18387
    Experimental

    GB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A.

  8. Drug

    PAS-004

    go.drugbank.com/drugs/DB18611
    Investigational

    PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.

  9. Drug

    Cardiopet

    go.drugbank.com/drugs/DB18913
    Investigational

    Cardiopet is under investigation in clinical trial NCT01826773 (Cardiopet as PET Imaging Agent to Assess Myocardial Perfusion and Fatty Acid Uptake in Known or Suspected CAD Subjects).

  10. Drug

    VIS-410

    go.drugbank.com/drugs/DB19067
    Investigational

    VIS-410 is under investigation in clinical trial NCT03040141 (Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A).